(Oncodesign) Novel PSMA+ and FAP+ mouse models to support the development of novel molecular radiotherapy agents
New radiotherapy development with genO-BRGSF
May 21, 2025
Abstract
- Robust preclinical models are required for the evaluation of novel PSMA-overexpressing mouse models molecular radiotherapies (MRT):
- accuratelymimicking human tumor microenvironments
- Expressing optimal levels of target proteins.
- Tow biomarkers of interest in the field of MRT and Oncology are:
1. Fibroblast activation protein (FAP): Minimally expressed in regular tissues, upregulated in cancer-associated fibroblasts within the tumor microenvironment.
2. Prostate-specific membrane antigen (PSMA): overexpressed in most prostate cancers.
- Oncodesign Services already had PSMA-overexpressing models available, but only on Balb/c Nude mice. This strain is radiosensitve due to a mutation and has become unavailable for purchase in the recent months.
- Furthermore, inherently expressing FAP models are available, but have minimal FAP-expression.
- To close the gap in our catalogue, Oncodesign Services has recently developed novel FAP and PSMA-overexpressing models in nonradiosensitve mouse strains.
Scientific excellence
From model design to experimental results
Featured in 600+ scientific articles
Collaborative approach
Collaboration with 17 Top Pharmas,
170+ Biotechs and 380+ Academic Institutions
Robust validation data on catalog models
Generated with biopharma partners and in-house
Innovative technologies
and guaranteed freedom to operate
Easy access to models
Models with certified health status from professional breeders in US and Europe